Smaller Biopharma M&A on Upswing, Deals Expected to Continue Through 2024
As evidenced by this week’s buyouts by J&J and Merck, Big Pharma appears to have found a sweet spot favoring smaller deals over megabillion-dollar acquisitions.
Smaller Biopharma M&A on Upswing, Deals Expected to Continue Through 2024 Read More »
